Tailored combo therapy boosts leukemia fight in adults
NCT ID NCT02881086
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This study tested a personalized, intensive treatment plan for adults aged 18-55 with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. The approach used strong chemotherapy, targeted drugs like nelarabine for T-cell ALL, and risk-based stem cell transplants. Over 1,000 participants were enrolled to see if this tailored strategy improves event-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital of Frankfurt (Main)
Frankfurt am Main, 60590, Germany
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.